Colon cancer progression is driven by APEX1-mediated upregulation of Jagged

48Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Aberrant expression of apurinic-apyrimidinic endonuclease-1 (APEX1) has been reported in numerous human solid tumors and is positively correlated with cancer progression; however, the role of APEX1 in tumor progression is poorly defined. Here, we show that APEX1 contributes to aggressive colon cancer behavior and functions as an upstream activator in the Jagged1/Notch signaling pathway. APEX1 overexpression or knockdown in human colon cancer cell lines induced profound changes in malignant properties such as cell proliferation, anchorage-independent growth, migration, invasion, and angiogenesis in vitro and in tumor formation and metastasis in mouse xenograft models. These oncogenic effects of APEX1 were mediated by the upregulation of Jagged1, a major Notch ligand. Furthermore, APEX1 expression was associated with Jagged1 in various colon cancer cell lines and in tissues from colon cancer patients. This finding identifies APEX1 as a positive regulator of Jagged1/Notch activity and suggests that it is a potential therapeutic target in colon cancers that exhibit high levels of Jagged1/Notch signaling.

Cite

CITATION STYLE

APA

Kim, M. H., Kim, H. B., Yoon, S. P., Lim, S. C., Cha, M. J., Jeon, Y. J., … You, H. J. (2013). Colon cancer progression is driven by APEX1-mediated upregulation of Jagged. Journal of Clinical Investigation, 123(8), 3211–3230. https://doi.org/10.1172/JCI65521

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free